The role of Iodine-123-labeled 15-(p-iodophenyl)-3R,S-methylpentadecanoic acid scintigraphy in the detection of local myocardial involvement of sarcoidosis

Kaminaga, Tatsuro; Takeshita, Touru; Yamauchi, Takayoshi; Kawamura, Hikaru; Yasuda, Masami

doi:10.1016/j.ijcard.2003.05.012

Cited by 29 publications

(18 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…123 I-BMIPP uptake is sensitively impaired by ischemia and other myocardial damages, and has been reported to be effective in detecting cardiac sarcoidosis [6]. Therefore, we have evaluated the value of the combined study of 18 F-FDG PET and 123 I-BMIPP SPECT for the assessment of cardiac involvement of sarcoidosis by comparing the findings with CMR.…”

Section: Discussionmentioning

confidence: 99%

Complementary appearance of glucose and lipid metabolism in cardiac sarcoidosis

Tadamura

Yamamuro

et al. 2007

International Journal of Cardiology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Complementary appearance of glucose and lipid metabolism in cardiac sarcoidosis

Tadamura

Yamamuro

et al. 2007

International Journal of Cardiology

View full text Add to dashboard Cite

“…Typically, thallium-201 scintigraphy shows focal perfusion deficits at rest, which improve or disappear on stress imaging (so called reverse redistribution). Fixed perfusion defects are common but non-specific and the reported sensitivity of thallium-201 varies from 24 to 58% [102,103]. Gallium-67 accumulation is thought to indicate active inflammatory change and has been used to predict the response to corticosteroids in pulmonary and cardiac disease [102,104].…”

Section: Nuclear Imaging In Csmentioning

confidence: 99%

Improving the diagnostic accuracy for detecting cardiac sarcoidosis

Wicks

Menezes

Elliott

2015

Expert Review of Cardiovascular Therapy

View full text Add to dashboard Cite

Cardiac sarcoid is a potentially fatal condition that presents with a wide range of clinical manifestations including conduction abnormalities, tachyarrhythmias, congestive heart failure, cardiomyopathy and sudden cardiac death. Small observational registries and non-comparative studies have described clinical evidence of cardiac involvement in 5% of patients with systemic sarcoid, yet autopsy studies suggest prevalence as high as 79%. This suggests that cardiac sarcoidosis (CS) is underdiagnosed in everyday clinical practice. The scarcity of data and lack of consensus on the most appropriate methods for detecting, monitoring and treating CS presents a significant diagnostic and therapeutic challenge. This review explores the potential impact of novel strategies, including multimodality imaging, on the diagnostic accuracy for detecting CS and treatment.

show abstract

“…While 67 Ga scan and 99m Tc-methoxyisobutylisonitrile ( 99m Tc-MIBI) myocardial perfusion scintigraphy have been utilized for detection of myocardial involvement, they are relatively insensitive in the early stages of the disease, possibly delaying therapy which can pose substantial risks. Delayed-enhanced cardiac MRI and PET imaging are the most promising emerging diagnostic modalities in this setting, and the role of other non-invasive modalities like ultrasonic tissue characterization [7,8] and iodine-123-labeled 15-(p-iodophenyl)-3R,S-methylpentadecanoic acid scintigraphy [9] have also been investigated.…”

Section: Cardiac Sarcoidosismentioning

confidence: 99%

Clinical Utility of FDG–PET and PET/CT in Non-malignant Thoracic Disorders

et al. 2010

View full text Add to dashboard Cite

There have been several endeavors made to investigate the potential role of 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography (FDG-PET) (and tracers) and PET-computed tomography imaging in various benign disorders, particularly those related to thoracic structures. These various conditions can be broadly categorized into three groups: (a) infectious diseases (mycobacterial, fungal, bacterial infection), (b) active granulomatous disease such as sarcoidosis, and (c) other non-infectious/inflammatory conditions or proliferative disorders (e.g., radiation pneumonitis, post-lung transplant lymphoproliferative disorders, occupational pleuropulmonary complications, and post-surgical conditions), all of which can demonstrate varying degrees of FDG uptake on PET scans based upon the degree of inflammatory activity. This article reviews the current state of this very important application of FDG-PET imaging.

show abstract

The role of Iodine-123-labeled 15-(p-iodophenyl)-3R,S-methylpentadecanoic acid scintigraphy in the detection of local myocardial involvement of sarcoidosis

Cited by 29 publications

References 15 publications

Complementary appearance of glucose and lipid metabolism in cardiac sarcoidosis

Complementary appearance of glucose and lipid metabolism in cardiac sarcoidosis

Improving the diagnostic accuracy for detecting cardiac sarcoidosis

Clinical Utility of FDG–PET and PET/CT in Non-malignant Thoracic Disorders

Contact Info

Product

Resources

About